These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 5763004

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Irreversible enzyme inhibitors. CXLII. Further studies on active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 5-(p-Aminophenoxypropyl)-2,4,6-triaminopyrimidine bearing a terminal sulfonyl fluoride.
    Baker BR, Meyer RB.
    J Med Chem; 1969 Jan; 12(1):104-7. PubMed ID: 5763003
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Irreversible enzyme inhibitors. 138. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 6-(p-aminomethylphenethyl)-- 2,4-diamino-5-(3,4-dichlorophenyl)pyrimidine with a terminal sulfonyl fluoride.
    Baker BR, Vermeulen NM.
    J Med Chem; 1969 Jan; 12(1):89-91. PubMed ID: 5763048
    [No Abstract] [Full Text] [Related]

  • 6. Irreversible enzyme inhibitors. CXXXVI. 2,4-Diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonylbenzamido)phenoxymethyl]pyrimidine, an active-site-directed irreversible inhibitor of dihydrofolic reductase. Effect of structure on isozyme specificity.
    Baker BR, Vermeulen NM.
    J Med Chem; 1969 Jan; 12(1):82-5. PubMed ID: 5763046
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Irreversible enzyme inhibitors. CXL. Active-site-directed irreversible inhibitors derived from 1-(3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine.
    Baker BR, Lourens GJ.
    J Med Chem; 1969 Jan; 12(1):95-101. PubMed ID: 5763050
    [No Abstract] [Full Text] [Related]

  • 11. Irreversible enzyme inhibitors. CXXXV. Effect of ring substitution on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(p-fluorosulfonyl-phenylureido)phenoxymethyl]pyrimidine.
    Baker BR, Vermeulen NM.
    J Med Chem; 1969 Jan; 12(1):79-81. PubMed ID: 5763045
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Irreversible enzyme inhibitors. CXIX. Active-site-directed irreversible inhibitors of dihydrofolic reductase with tissue specificity derived from 2,4,6-triaminopyrimidine with a terminal sulfonyl fluoride at the 5 position.
    Baker BR, Meyer RB.
    J Med Chem; 1968 May; 11(3):489-94. PubMed ID: 5241408
    [No Abstract] [Full Text] [Related]

  • 14. Irreversible enzyme inhibitors. 178. Active-site-directed irreversible inhibitors of dihydrofolate reductase derived from 1-(4-benzyloxy-3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine with a terminal sulfonyl fluoride.
    Baker BR, Ashton WT.
    J Med Chem; 1970 Nov; 13(6):1161-5. PubMed ID: 5479857
    [No Abstract] [Full Text] [Related]

  • 15. Irreversible enzyme inhibitors. CXII. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine substituted with a terminal sulfonyl fluoride. II.
    Baker BR, Lourens GJ.
    J Med Chem; 1968 Jan; 11(1):38-41. PubMed ID: 5237173
    [No Abstract] [Full Text] [Related]

  • 16. Irreversible enzyme inhibitors. CXX. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 6-substituted 2,4-diamino-5-phenylpyrimidines with tissue specificity.
    Baker BR, Huang PC.
    J Med Chem; 1968 May; 11(3):495-500. PubMed ID: 5241409
    [No Abstract] [Full Text] [Related]

  • 17. Irrevesible enzyme inhibitors. CLI. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 5-(p-aminophenylbutyl)-2,4-diaminopyrimidines with a terminal sulfonyl fluoride.
    Baker BR, Meyer RB.
    J Med Chem; 1969 Mar; 12(2):224-7. PubMed ID: 5254099
    [No Abstract] [Full Text] [Related]

  • 18. Irreversible enzyme inhibitors. CIX. Candidate irreversible inhibitors of dihydrofolic reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine. 3.
    Baker BR, Lourens GJ.
    J Med Chem; 1968 Jan; 11(1):26-33. PubMed ID: 5237171
    [No Abstract] [Full Text] [Related]

  • 19. Irreversible enzyme inhibitors. CLXXIX. Active-site-directed irreversible enzyme inhibitors of dihydrofolate reductase from 1-(3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine with oxyamide bridges to a terminal sulfonyl fluoride.
    Baker BR, Ashton WT.
    J Med Chem; 1970 Nov; 13(6):1165-70. PubMed ID: 5479858
    [No Abstract] [Full Text] [Related]

  • 20. Irreversible enzyme inhibitors. CLIX. Effect of substitution on transport and isozyme specificity of p-(4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazin-1-yl)-o-chlorophenoxyacetamido-benzenesulfonyl fluoride, an active-site-directed irreversible inhibitor of dihydrofolic reductase.
    Baker BR, Ashton WT.
    J Med Chem; 1969 Sep; 12(5):894-7. PubMed ID: 5812207
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.